Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 18/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2362102 | 0.84 | GPBAR1 (0.47) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2361428 | 0.75 | GPBAR1 (0.35) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2361805 | 0.73 | POLB (0.40) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2C19 | |
| SCHEMBL2361852 | 0.71 | GPBAR1 (0.47) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2361834 | 0.70 | GPBAR1 (0.47) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2360946 | 0.70 | GPBAR1 (0.32) | GPBAR1NPC1 | |
| SCHEMBL2334546 | 0.67 | GPBAR1 (0.78) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2335696 | 0.66 | GPBAR1 (0.60) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2329971 | 0.66 | GPBAR1 (0.60) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 | |
| SCHEMBL2338902 | 0.66 | GPBAR1 (0.70) | GPBAR1CYP3A4CYP2C9CYP1A2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | claimed |
| EP-2356094-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | claimed |
| WO-2010049302-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | claimed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | claimed |
| US-8309734-B2 | Substituted pyridines as GPBAR1 agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-11-13 | — | — | US | disclosed |
| EP-2356094-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010049302-A1 | NOVEL PHENYL AMIDE OR PYRIDIL AMIDE DERIVATIVES AND THEIR USE AS GPBAR1 AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-05-06 | — | — | WO | disclosed |
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) | 2010-04-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100105906-A1 | NOVEL PHENYL AMIDE OR PYRIDYL AMIDE DERIVATIVES | GPBAR1, GPR119, GLP1R | GPBAR1 1/4885CYP3A4 1330/4885CYP2C9 1256/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.